Network meta-analysis: Dipeptidyl peptidase-4 inhibitors increase the risk of cholecystitis in patients with type 2 diabetes. 29 Jun, 2022 | 11:24h | UTC Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials – The BMJ